跳轉至內容
Merck
  • Correlation of (18)F-FDG avid volumes on pre-radiation therapy and post-radiation therapy FDG PET scans in recurrent lung cancer.

Correlation of (18)F-FDG avid volumes on pre-radiation therapy and post-radiation therapy FDG PET scans in recurrent lung cancer.

International journal of radiation oncology, biology, physics (2014-04-15)
Nadya Shusharina, Joseph Cho, Gregory C Sharp, Noah C Choi
摘要

To investigate the spatial correlation between high uptake regions of 2-deoxy-2-[(18)F]-fluoro-D-glucose positron emission tomography ((18)F-FDG PET) before and after therapy in recurrent lung cancer. We enrolled 106 patients with inoperable lung cancer into a prospective study whose primary objectives were to determine first, the earliest time point when the maximum decrease in FDG uptake representing the maximum metabolic response (MMR) is attainable and second, the optimum cutoff value of MMR based on its predicted tumor control probability, sensitivity, and specificity. Of those patients, 61 completed the required 4 serial (18)F-FDG PET examinations after therapy. Nineteen of 61 patients experienced local recurrence at the primary tumor and underwent analysis. The volumes of interest (VOI) on pretherapy FDG-PET were defined by use of an isocontour at ≥50% of maximum standard uptake value (SUVmax) (≥50% of SUVmax) with correction for heterogeneity. The VOI on posttherapy images were defined at ≥80% of SUVmax. The VOI of pretherapy and posttherapy (18)F-FDG PET images were correlated for the extent of overlap. The size of VOI at pretherapy images was on average 25.7% (range, 8.8%-56.3%) of the pretherapy primary gross tumor volume (GTV), and their overlap fractions were 0.8 (95% confidence interval [CI]: 0.7-0.9), 0.63 (95% CI: 0.49-0.77), and 0.38 (95% CI: 0.19-0.57) of VOI of posttherapy FDG PET images at 10 days, 3 months, and 6 months, respectively. The residual uptake originated from the pretherapy VOI in 15 of 17 cases. VOI defined by the SUVmax-≥50% isocontour may be a biological target volume for escalated radiation dose.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
D -(+)-葡萄糖, ≥99.5% (GC)
Sigma-Aldrich
D -(+)-葡萄糖, powder, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99.5%
Sigma-Aldrich
D -(+)-葡萄糖 溶液, 45% in H2O, sterile-filtered, BioXtra, suitable for cell culture
Sigma-Aldrich
D -(+)-葡萄糖 溶液, 100 g/L in H2O, sterile-filtered, BioXtra, suitable for cell culture
Sigma-Aldrich
葡萄糖, 97.5-102.0% anhydrous basis, meets EP, BP, JP, USP testing specifications
Sigma-Aldrich
D -(+)-葡萄糖, ≥99.5% (GC), BioXtra
USP
右旋糖, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
紫杉醇, from semisynthetic, ≥98%
Sigma-Aldrich
D -(+)-葡萄糖, BioUltra, anhydrous, ≥99.5% (sum of enantiomers, HPLC)
Sigma-Aldrich
紫杉醇, from Taxus brevifolia, ≥95% (HPLC), powder
Supelco
D -(+)-葡萄糖, analytical standard
Sigma-Aldrich
卡铂
Sigma-Aldrich
L - (−) -葡萄糖, ≥99%
Sigma-Aldrich
D -(+)-葡萄糖, suitable for mouse embryo cell culture, ≥99.5% (GC)
Sigma-Aldrich
D -(+)-葡萄糖, ACS reagent
Sigma-Aldrich
紫杉醇, from Taxus yannanensis, powder
Sigma-Aldrich
D -(+)-葡萄糖, Hybri-Max, powder, BioReagent, suitable for hybridoma
Sigma-Aldrich
2-氟-2-脱氧-D-葡萄糖, glycosylation inhibitor, glucose analog
Supelco
葡萄糖, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
D-葡萄糖-12C6, 16O6, 99.9 atom % 16O, 99.9 atom % 12C
紫杉醇, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
D -(+)-葡萄糖, Vetec, reagent grade, ≥99.5% (HPLC)
Supelco
D -(+)-葡萄糖 溶液, 1 mg/mL in 0.1% benzoic acid, standard for enzymatic assay kits GAGO20, GAHK20, STA20, analytical standard
Sigma-Aldrich
D -(+)-葡萄糖, tested according to Ph. Eur.
峰鉴别用天然紫杉醇, European Pharmacopoeia (EP) Reference Standard
紫杉醇, European Pharmacopoeia (EP) Reference Standard
紫杉醇, European Pharmacopoeia (EP) Reference Standard